Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 03, 2015 6:50 PM ET


Company Overview of Endocyte, Inc.

Company Overview

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical develop...

3000 Kent Avenue

Suite A1-100

West Lafayette, IN 47906

United States

Founded in 1995

81 Employees





Key Executives for Endocyte, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $475.6K
Co-Founder, Chief Scientific Officer and Director
Age: 67
Total Annual Compensation: $208.7K
Chief Financial Officer and Chief Operating Officer
Age: 49
Total Annual Compensation: $323.0K
Vice President of Research & Development
Age: 49
Total Annual Compensation: $278.5K
Vice President of Clinical Operations
Age: 58
Total Annual Compensation: $261.8K
Compensation as of Fiscal Year 2014.

Endocyte, Inc. Key Developments

Endocyte, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Endocyte, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced collaboration revenue of $12,000 compared to $17,269,000 for the same period a year ago. Loss from operations was $10,965,000 compared to $3,219,000 for the same period a year ago. Net loss was $10,870,000 compared to $3,141,000 for the same period a year ago. Net loss per share, basic and diluted was $0.26 compared to $0.09 for the same period a year ago.

Endocyte, Inc., Q1 2015 Earnings Call, May 07, 2015

Endocyte, Inc., Q1 2015 Earnings Call, May 07, 2015

Endocyte, Inc. Appoints P. David Mozley, M.D. as Vice President of Imaging

Endocyte, Inc. announced that P. David Mozley, M.D. has been appointed as vice president of imaging. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan.

Similar Private Companies By Industry

Company Name Region
zuSyn, Inc. United States
Cytosol Laboratories, Inc. United States
MedImmune Vaccines, Inc. United States
Aprecia Pharmaceuticals Company United States
Neurion Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Endocyte, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at